Progress toward HIV cure highlighted in issue of AIDS Research & Human Retroviruses

February 10, 2017

New Rochelle, NY, Feb. 9, 2017 -- A comprehensive collection of articles describing the broad scope and current status of this global effort is published in a special issue of AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The third annual Special Issue on HIV Cure Research is available free on the AIDS Research and Human Retroviruses website.

Leonardo Calza and coauthors from University of Bologna (Italy), have shown that statins, which are commonly prescribed to lower blood lipid levels, can also significantly reduce the concentration of D-dimer, a marker of coagulation, and of two markers of inflammation known as interleukins (IL-8 and IL-10) in HIV-infected individuals. The anti-inflammatory properties of statins and their potential effects on blood clot formation could help reduce HIV-associated comorbidities such as cardiovascular disease. The researchers present their findings in the article entitled "Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy."

In the article "Lower Frailty Is Associated with Successful Cognitive Aging Among Older Adults with HIV," Lindsay Wallace and coauthors from Dalhousie University (Halifax, Canada), University of Modena and Reggio Emilia (Modena, Italy), and University of California San Diego, identified factors associated with better cognitive function among HIV-infected individuals 50 years of age or older being treated with combination antiretroviral therapy. The researchers found that study participants who scored lower on a frailty index were less likely to have neurocognitive impairment.

Heather Grome and colleagues from Vanderbilt University Medical Center (Nashville, TN), report on the role that persistent T-cell and macrophage activation in HIV-infected adults on combination antiretroviral therapy may have on the function of arterial blood vessels. The effects of HIV-related chronic immune activation on the arterial lining and vascular smooth muscle may promote the development of atherosclerosis and plaque formation that can lead to cardiovascular disease. The researchers present measures of blood-based inflammatory and immune activation markers and the results of brachial artery flow-mediated dilation on ultrasound in the article entitled "Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIV."

"It is becoming clear that although HIV-infected individuals can control the amount of virus in their system with antiviral treatments, there are still negative health consequences that look like premature aging, including cardiovascular disease and cognitive impairment," says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine (Chicago, IL). "These three papers and others in the Cure issue seek a better understanding of the cause of this accelerated aging. The Calza article suggests that taking statins, which reduce lipid levels, may be an effective treatment to reduce damaging inflammation in HIV-infected individuals taking appropriate antiviral therapy,"
-end-
Research reported by Grome et al. was supported by the National Institutes of Health under Award Numbers K23 100700, K24 AI65298, UL1 RR024975-01, and P30 AI110527. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Journal

AIDS Research and Human Retroviruses, published monthly online with open access options and in print, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. Content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information, reports on clinical trials of emerging HIV therapies, and images in HIV research. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs, Viral Immunology, and Journal of Interferon and Cytokine Research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: 914-740-2100 (800) M-LIEBERT Fax: 914-740-2101

Mary Ann Liebert, Inc./Genetic Engineering News

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.